Skip to main content
Equibles

ATHE · Alterity Therapeutics Ltd

Track ATHE — free

Use ATHE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATHE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.45 +0.02 (+0.89%)
Rebalance outlook locked
Market Cap
$44.61M
Shares
18.21M
Volume · Oct 20 15.97K Avg daily vol (3M) 18.73K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.43 Open$2.65 Day$2.43–2.66 52W close$2.43–5.89 Avg vol 30d25K Short int26K · 0.1% float · 2.2d Short vol37% Last earningsDec 31, 2020 DataJan 2020–Oct 2026

Up next

Q2 2021 earnings call transcript
Date not confirmed

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+88.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-97.6%
Year over year · fewer shares
Price change (1Y)
-50.3%
Trailing year
Short interest
0.1%
Latest settlement · 2.2 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −40%
below
Price vs 50-day avg −38%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −36%
trailing
6-month return −47%
trailing
YTD return −21%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
4 of 21 funds reported for Sep 30 · net -686 sh shares
Insider flow Accumulating
Net +$23.8K over 90 days · 0% sells
Short interest Rising
0.14% of float · ▲ +1.7% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
21 holders — near 3-yr high, broad support
Squeeze score 33
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −59%
past year
ATR 12.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
5 · 2 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−40% Bearish
Price vs 50-day avg
−38% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) Death cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
4 of 21 funds reported for Sep 30 · net -686 sh shares
Insider flow Accumulating
Net +$23.8K over 90 days · 0% sells
Short interest Rising
0.14% of float · ▲ +1.7% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
21 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $6
vs 200-day avg -40% vs 50-day avg -38% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATHE
Alterity Therapeutics Ltd
this stock
$44.61M -21.1% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
21
% held
2.2%
Reported
4 of 21
Top holder
Twin Lakes Capital Manage…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
26.1K
Days to cover
2.2d
Change
+447 sh
View
Short Volume
Short vol %
37%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
5.0K
Value
$18.0K
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
56.9%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$23.8K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 19, 2026
This year
76

Alterity Therapeutics announced that CEO David Stamler, M.D., will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, October 22, 2026 at 2:30 p.m. ET.

View
Earnings & Events
Webcasts
Last webcast
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
ATHE -17.1% -35.7% -46.9% -33.4% -21.1%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -15.6% -34.8% -54.6% -33.9% -33.5%
Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 4 filings 4 filers Visit website Investor relations